A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
Study Details
Study Description
Brief Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC in local advanced or metastatic gastric patients with the overexpression of HER2.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: RC48-ADC Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first). |
Drug: RC48-ADC
2.5 mg/kg IV every 2 weeks
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate （ORR） [up to 24 months]
Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)
Secondary Outcome Measures
- Progression Free Survival (PFS) as Assessed by investigator [up to 24 months]
Tumor response was assessed by investigator according to RECIST v1.1
- Overall Survival(OS) [up to 24 months]
OS was defined as the time from the first study treatment to the date of death from any cause
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Voluntary agreement to provide written informed consent.
-
Male or female, Age ≥ 18 years and ≤ 80 years.
-
Predicted survival ≥ 12 weeks.
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
-
All female subjects will be considered to be of child-bearing potential unless they are postmenopausal, or have been sterilized surgically.Female subjects of child-bearing potential must agree to use two forms of highly effective contraception. Male subjects and their female partner who are of child-bearing potential must agree to use two forms of highly effective contraception.
-
Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
-
Adequate organ function.
-
Have had progression or intolerance following receipt of at least two systemic chemotherapy for advanced or metastatic disease.
-
HER2 overexpression defined as HER2 IHC 2+ or 3+.
-
Measurable disease according to RECIST 1.1.
Exclusion Criteria:
-
Known hypersensitivity to Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection.
-
History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to trial treatment.
-
History of major surgery within 4 weeks of planned start of trial treatment.
-
Has received a live virus vaccine within 4 weeks of planned start of trial treatment.
-
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
-
History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.
-
Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing Cancer Hospital | Beijing | Beijing | China | 100142 |
Sponsors and Collaborators
- RemeGen Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RC48-C008